Newron Pharmaceuticals S.p.A. (SWX: NWRN)

Newron Pharmaceuticals Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2023	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2.81	2.81	1.36	2.87	1.77	1.53
Cash & Short-Term Investments	2.81	2.81	1.36	2.87	1.77	1.53
Cash Growth	106.24%	106.24%	-52.54%	61.96%	15.89%	-81.88%
Accounts Receivable	8.31	8.31	7.17	4.86	8.58	8.32
Other Receivables	1.46	1.46	2.46	2.05	1.86	2.74
Receivables	10.14	10.14	10.03	7.32	11.55	12.11
Inventory	21.37	21.37	13.59	18.87	14.27	19.76
Other Current Assets	7.95	7.95	6.23	2.88	3.91	6.97
Total Current Assets	42.27	42.27	31.21	31.95	31.5	40.37
Property, Plant & Equipment	47.44	47.44	41.63	45.84	25.36	20.48
Long-Term Investments	-	-	-	-	3.64	2.67
Other Intangible Assets	12.87	12.87	9.66	6.29	5.38	5.03
Long-Term Accounts Receivable	-	-	-	-	1.73	0.27
Other Long-Term Assets	1.82	1.82	6.18	3.25	4.03	4.27
Total Assets	106.05	106.05	90.82	89.68	73.23	73.09
Accounts Payable	12.6	12.6	10.84	12.08	10.56	8.2
Accrued Expenses	14.71	14.71	14.61	16.65	12.81	16
Current Portion of Long-Term Debt	2.32	2.32	18.87	13.99	30.34	17.47
Current Portion of Leases	2.67	2.67	2.74	3	1.95	1.87
Current Unearned Revenue	8.12	8.12	7.42	6.79	9.48	1.6
Other Current Liabilities	30.03	30.03	18.12	7.05	7.71	5.89
Total Current Liabilities	70.45	70.45	72.6	59.55	72.85	51.03
Long-Term Debt	68.83	68.83	52.66	34.21	9.06	20.74
Long-Term Leases	18.78	18.78	19.65	21.89	5.84	3.16
Long-Term Deferred Tax Liabilities	-	-	-	-	-	0.39
Other Long-Term Liabilities	0	0	0	-	0.82	-0
Total Liabilities	160.81	160.81	144.91	115.65	94.75	85.82
Common Stock	58.61	58.61	44.48	33.52	26.01	15.38
Additional Paid-In Capital	0.29	0.29	30.67	56	55.46	16.59
Retained Earnings	-112.74	-112.74	-132.37	-112.82	-93.88	-31.4
Comprensive Income & Other	-3.58	-3.58	3.13	-2.67	-9.1	-13.3
Total Common Equity	-57.41	-57.41	-54.08	-25.97	-21.52	-12.73
Minority Interest	2.66	2.66	-	-	-	-
Shareholders' Equity	-54.75	-54.75	-54.08	-25.97	-21.52	-12.73
Total Liabilities & Equity	106.05	106.05	90.82	89.68	73.23	73.09
Total Debt	92.6	92.6	93.91	73.09	47.19	43.25
Net Cash (Debt)	-89.8	-89.8	-92.55	-70.22	-45.42	-41.72
Net Cash Per Share	-0.17	-0.17	-0.26	-0.23	-0.24	-0.31
Filing Date Shares Outstanding	586.11	586.11	444.81	335.2	260.07	153.82
Total Common Shares Outstanding	586.11	586.11	444.81	335.2	260.07	153.82
Working Capital	-28.18	-28.18	-41.39	-27.6	-41.35	-10.66
Book Value Per Share	-0.10	-0.10	-0.12	-0.08	-0.08	-0.08
Tangible Book Value	-70.28	-70.28	-63.74	-32.26	-26.9	-17.76
Tangible Book Value Per Share	-0.12	-0.12	-0.14	-0.10	-0.10	-0.12
Machinery	44.15	44.15	46.13	47.16	38.04	35.72
Construction In Progress	11.24	11.24	1.11	1.54	5.58	2.73

Source: S&P Capital IQ. Standard template. Financial Sources.